Metagenomi Extends RA Capital’s Series A Funding, Welcomes Andrew Levin to Its Board of Directors
EMERYVILLE, Calif .– (COMMERCIAL THREAD) –Metagenome, a gene-editing company, today announced the extension and closure of its Series A funding, bringing the round to a total of $ 75 million. This cycle will support the expansion of the Metagenomi team and the development of the company’s therapeutic pipeline. RA Capital Management joins the syndicate of Series A investors, comprising co-investors Leaps by Bayer and Humboldt Fund, as well as Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital, after the first close of the Series A financing, which was announced in November 2020. Andrew Levin, MD, Ph.D., Managing Director of RA Capital, will join the Board of Directors of Metagenomi.
“Metagenomics’ technology and its deep scientific foundation in the field of metagenomics enable new clinical solutions for patients as the company emerges as a new leader in therapeutic publishing,” noted Dr. Levin. “Where most approaches and pipelines are built on a single system, Metagenomi’s diverse toolbox of gene editing systems will enable the company to match the best technology to unmet medical needs. ”
“The AR team adds to the diverse range of expertise at our table as we move towards the clinic with our in vivo and ex vivo therapies and explore new opportunities for our technologies, ”said Brian C. Thomas, Ph.D., co-founder and CEO of Metagenomi. “We are excited and encouraged by the continued interest in Metagenomi that we have seen from visionary partners in the field and look forward to advancing our disease cure goals. ”
About Metagenomi
At Metagenomi, we are accelerating innovation in cell and gene therapy with a wave of proprietary CRISPR-based systems to precisely edit DNA where current technologies cannot. Our metagenomics-based discovery platform and analytical expertise reveal new cellular machinery from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful therapeutic tools that can be harnessed by partners and fuel our own pipeline of potentially curative drugs. Our goal is to revolutionize gene editing and unleash its power for the benefit of patients around the world. For more information, please visit https://metagenomi.co/
About RA Capital Management
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that develop drugs, medical devices and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and lead private funding, IPOs and follow-on funding for its portfolio companies, enabling management teams to drive the creation of new companies. value from start to market. https://www.racap.com/
Follow us on twitter: @metagenomi